In This Section

Collaborations

NeuVax™ (nelipepimut-S) — PRESENT Study

Target: Node positive HER2 negative breast cancer (low-to-intermediate expression, IHC levels of 1+ or 2+ and a FISH rating of less than 2.0) – Phase 3 PRESENT Trial under FDA-approved SPA

Teva LogoLeica LogoKwang Dong LogoDr. Reddy's Logo

NeuVax™ + Herceptin® (trastuzamab)

Target: Node positive HER2 negative breast cancer (low-to-intermediate expression, IHC levels of 1+ or 2+ and a FISH rating of less than 2.0) – Phase 2b

Genentech LogoRoche LogoHJF Logo

NeuVax™ + Herceptin® (trastuzamab), HER2 3+

Target:HER2 3+ breast cancer patients who have completed neoadjuvant therapy with an approved regimen that includes trastuzumab and fail to achieve a pathological complete response – Phase 2

Department of Defense

NeuVax™ — VADIS Study

Target:Ductal Carcinoma in Situ (DCIS) HLA A2+ – Phase 2 planned